Awakn Life Sciences (XCNQ:AWKN) EBIT per Share : C$-0.39 (TTM As of Oct. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences EBIT per Share?

Awakn Life Sciences's EBIT per Share for the three months ended in Oct. 2023 was C$-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2023 was C$-0.39.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Awakn Life Sciences's EBIT per Share or its related term are showing as below:

XCNQ:AWKN's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Awakn Life Sciences's EBIT for the three months ended in Oct. 2023 was C$-0.68 Mil.

Awakn Life Sciences EBIT per Share Historical Data

The historical data trend for Awakn Life Sciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences EBIT per Share Chart

Awakn Life Sciences Annual Data

Trend

Jan21

Jan22

Jan23

EBIT per Share

-0.05

-0.74

-0.37

Awakn Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
EBIT per Share	Get a 7-Day Free Trial							-0.04	-0.25	-0.06	-0.05	-0.02

Awakn Life Sciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Awakn Life Sciences's EBIT per Share for the fiscal year that ended in Jan. 2023 is calculated as

	EBIT per Share		(A: Jan. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.385	/	25.203
=	-0.37

Awakn Life Sciences's EBIT per Share for the quarter that ended in Oct. 2023 is calculated as

	EBIT per Share		(Q: Oct. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.675	/	30.511
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.39

Awakn Life Sciences (XCNQ:AWKN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Awakn Life Sciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Awakn Life Sciences (XCNQ:AWKN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (XCNQ:AWKN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AWKNF:USA 954:Germany

Address

301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2

Website

https://www.awaknlifesciences.com

Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences (XCNQ:AWKN) Headlines

No Headlines